Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jul;55(7):3240-3.
doi: 10.1128/AAC.01680-10. Epub 2011 May 16.

Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults

Aaron M Cook  1 , Craig Martin, Val R Adams, R Scott Morehead
Affiliations
Clinical Trial

Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults

Aaron M Cook et al. Antimicrob Agents Chemother. 2011 Jul.

Abstract

The physiochemical properties of levofloxacin suggest that it is an agent which may exhibit altered pharmacokinetics in obese individuals. The purpose of this study was to describe the pharmacokinetics of a single 750-mg intravenous dose of levofloxacin in both hospitalized and ambulatory obese individuals. The hypothesis was that a standard dose of levofloxacin in obese individuals would achieve serum concentrations likely to be therapeutic. A single levofloxacin dose of 750 mg was infused over 90 min, and seven serial serum samples were subsequently obtained to evaluate the pharmacokinetics after the first dose. The peak concentrations of levofloxacin were comparable to those seen with normal-weight individuals. However, the area under the concentration-time curve and clearance were quite variable. Accelerated clearance was evident in the ambulatory obese individuals. Further investigation of the effects of obesity on the pharmacokinetics of levofloxacin is necessary to ensure optimal dosing.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Pharmacokinetic model.
Fig. 2.
Fig. 2.
Pharmacokinetic profile of intravenous levofloxacin administered at 750 mg in obese adults.
Fig. 3.
Fig. 3.
Comparison of estimated and measured creatinine clearance versus levofloxacin clearance.
See this image and copyright information in PMC

References

    1. Allard S., Kinzig M., Boivin G., Sorgel F., LeBel M. 1993. Intravenous ciprofloxacin disposition in obesity. Clin. Pharmacol. Ther. 54:368–373 - PubMed
    1. Ambrose P. G., et al. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793–2797 - PMC - PubMed
    1. Blouin R. A., Warren G. W. 1999. Pharmacokinetic considerations in obesity. J. Pharm. Sci. 88:1–7 - PubMed
    1. Boucher B. A., Hanes S. D. 1998. Pharmacokinetic alterations after severe head injury. Clin. Pharmacokinet. 35:209–221 - PubMed
    1. Chien S.-C., et al. 1997. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob. Agents Chemother. 41:1562–1565 - PMC - PubMed

Publication types

LinkOut - more resources